BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GI Innovation\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies GI Innovation\, Inc.'s drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07172802-2495@assetmemo.bio
DTSTAMP:20261121T010140Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:GI-108: Phase 1/2 readout est. (NCT07172802)
DESCRIPTION:GI-108\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y of GI-108\, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein\, as Mo
 notherapy in Patients With Advanced or Metastatic Solid Tumors\nEstimated 
 primary completion: February 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/gi-108#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07172802
URL:https://assetmemo.bio/drug/gi-108#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04977453-2493@assetmemo.bio
DTSTAMP:20261121T010140Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Efdelikofusp alfa: Phase 1/2 readout est. (NCT04977453)
DESCRIPTION:Efdelikofusp alfa\, phase 1/2\, Non-Small Cell Lung Cancer.\nSt
 udy: GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab
  or Lenvatinib in Advanced Solid Tumors\nEstimated primary completion: 30 
 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/efdelikofu
 sp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04977453
URL:https://assetmemo.bio/drug/efdelikofusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
